Introduction {#section1-2150131916687888}
============

Affecting an estimated 53.6 million Americans aged 50 years and older, osteoporosis and osteopenia are common disorders responsible for an estimated 2 million fractures annually.^[@bibr1-2150131916687888]^ Significant improvements in the secondary prevention of osteoporotic fractures have been noted with the widespread use of fracture liaison services (FLS).^[@bibr2-2150131916687888],[@bibr3-2150131916687888]^ Other efforts to address secondary prevention have reported limited success.^[@bibr4-2150131916687888][@bibr5-2150131916687888][@bibr6-2150131916687888][@bibr7-2150131916687888]-[@bibr8-2150131916687888]^ With a projected 3 million fractures and an associated \$25.3 billion in health care costs annually by 2025,^[@bibr9-2150131916687888]^ improved primary prevention is critical. Bone mineral density (BMD) screening and early intervention are obvious targets for improving prevention of first fracture. Despite this critical need, few models for the primary prevention of fragility fractures have been described,^[@bibr10-2150131916687888],[@bibr11-2150131916687888]^ and no team-based primary interventions reported.

Published reports continue to document low osteoporosis screening and treatment rates.^[@bibr12-2150131916687888],[@bibr13-2150131916687888]^ A systematic review of 51 articles found that less than a third of at-risk women received BMD testing.^[@bibr15-2150131916687888]^ Another study based on Medicare claims during 2002 to 2008 found that less than half of all elderly women had ever had a BMD test.^[@bibr16-2150131916687888]^ Among males, only about 7% of men received a diagnosis for osteoporosis following a fragility fracture, and even fewer received a BMD scan or received treatment within 1 year.^[@bibr13-2150131916687888][@bibr14-2150131916687888]-[@bibr15-2150131916687888],[@bibr17-2150131916687888],[@bibr18-2150131916687888]^ To date, no studies have examined reasons for low screening and treatment in the specific context of male osteoporosis, although data in women suggests that there is considerable uncertainty on the parts of clinicians about how to use BMD test results,^[@bibr19-2150131916687888],[@bibr20-2150131916687888]^ unfamiliarity with osteoporosis treatment guidelines,^[@bibr21-2150131916687888]^ and ambiguity about whose role it is to prescribe preventive therapies.^[@bibr22-2150131916687888]^

To address this important issue, we partnered with primary care providers (PCPs) within the Salt Lake City Veterans Affairs Health Care System (SLCVAHCS) to develop a Bone Health Team (BHT) consisting of an endocrinologist, a pharmacist, and a nurse practitioner dedicated to the screening and management of patients at risk for osteoporotic fractures. The BHT manages the screening, diagnosis, treatment, and ongoing monitoring of osteoporosis, on behalf of PCPs, through a collaborative care agreement, using virtual and telephone clinics.

Methods {#section2-2150131916687888}
=======

Patient Enrollment and Care Coordination {#section3-2150131916687888}
----------------------------------------

The Veterans Affairs Salt Lake City Health Care System Bone Health Team was established in January 2013 and includes an endocrinologist, a clinical pharmacist, and a nurse practitioner. A collaborative care agreement was established with the Chief of Community-Based Outpatient Clinics and allows for the BHT to enroll patients from any of the 7 community-based outpatient clinics (CBOCs).

Lists of patients treated by PCPs constitute "PCP panels." We generated PCP panels using data available from the Veterans Affairs corporate data warehouse. The BHT evaluated the PCP panels and identified patients with osteoporosis risk factors. The most common risk factor used by the BHT to justify bone density screening was patient age. The BHT offered screening to men aged 70 years and older and women aged 65 years and older. Younger patients (aged 50 years and older) with risk factors were eligible for enrollment in the BHT; however, in order to create a cohort that is readily comparable to non-BHT patients, this analysis describes only the patients that were enrolled based on age.

The BHT reviewed the entire PCP panel for an individual provider before proceeding to the next provider. So far, the BHT has completed screening the patient panels of 5 providers from one CBOC and has partially completed the screening of a sixth provider from a second CBOC.

Patients were contacted via telephone or letter, and all patient care activities were conducted using virtual and telephone clinics. The BHT managed the patient's entire osteoporosis care including screening, diagnosis, medication and nonmedication interventions, and ongoing follow-up. When providing patient care, BHT included the PCP as a cosigner to progress notes, thereby keeping the PCP informed and involved.

Bone Health Team Interventions {#section4-2150131916687888}
------------------------------

Screening: The BHT screened patients bone density using dual energy x-ray absorptiometry (DXA). Patients with osteopenia (*T*-score between −1 and −2.5) or osteoporosis (*T*-score −2.5 or worse) were evaluated for underlying causes. The BHT ordered serum chemistry; serum parathyroid hormone if any history of stage 3 or worse chronic kidney disease, or if a history of calcium or parathyroid hormone abnormalities; 25-hydroxy-vitamin D levels; and testosterone levels if not previously evaluated and patient had other symptoms consistent with possible hypogonadism. If abnormalities were identified during this evaluation, the corresponding potential underlying conditions were evaluated further.

In broad terms, the BHT generally used a bone active drug (oral or intravenous bisphosphonate, subcutaneous denosumab, or subcutaneous teriparatide) to treat patients. The rationale that the BHT used to help determine treatment threshold were: generally treat patients with osteoporosis; generally treat if fracture risk of 3% or more at the hip, or 20% or more major osteoporotic fracture risk based on FRAX risk assessment with BMD for patients with osteopenia,^[@bibr14-2150131916687888]^ include guidance from American College of Rheumatology clinical practice guidelines for patients on chronic glucocorticoids,^[@bibr15-2150131916687888]^ and include guidance from endocrine society clinical practice guidelines for men with hypogonadism and men receiving androgen deprivation therapy.^[@bibr16-2150131916687888]^

In addition to pharmacotherapy, the BHT evaluated dietary and supplemental intake of calcium and vitamin D, as well as fall history, fall risk, and weightbearing activity history. The BHT discussed pertinent social history, including alcohol and tobacco use. Based on patient risk factors, BHT made appropriate recommendations, including supplementation of calcium and/or vitamin D if currently insufficient, referrals to physical therapy for core muscle strengthening and balance, referral to occupational therapy for a home safety evaluation, referral to smoking cessation, and encouraging weightbearing activities.

Study Design and Patients {#section5-2150131916687888}
-------------------------

This historical cohort analysis of the BHT described the outcomes of the SLC VA BHT for patients in the CBOCs of the SLCVAHCS from February 1, 2012 through February 1, 2015. Men aged 70 years and older and women aged 65 years and older were included in our cohort. Patients who were not assigned to VA SLC CBOC PCP panel, did not have a PCP appointment in the preindex period, or who died during the preindex period, were excluded from the study. Covariates (summarized in [Table 1](#table1-2150131916687888){ref-type="table"}) were defined in the 1-year preindex period of February 1, 2012 to February 1, 2013 (the year prior to the implementation of the BHT). This analysis was reviewed by the institutional review board of the SLCVAMC and determined to be a quality-of-care analysis and exempt from human subjects review.

###### 

Patient Demographics for Patients Enrolled in the Bone Health Team (BHT) Versus Nonenrolled Patients (No BHT).

![](10.1177_2150131916687888-table1)

                                      BHT, N = 975   No BHT, N = 6669   *P*           
  ----------------------------------- -------------- ------------------ ------ ------ ---------
  *Demographics*                                                                      
  Age (years)                                                                         
   65-74                              294            30.2               1590   23.8   .000
   75-80                              223            22.9               1716   25.7   
   80-85                              243            24.9               1740   26.1   
   85+                                215            22.1               1623   24.3   
  Male                                953            97.7               6534   98.0   .633
  Rural zip code                      827            84.8               4053   60.8   \<.0001
  Married                             260            26.7               1842   27.6   .533
  White                               672            68.9               4185   62.8   .000
  Non-VA insurance                    958            98.3               6421   96.3   .002
  Primary care provider type                                                          
   Physician                          413            42.4               2099   31.5   \<.0001
   Physician's assistant              25             2.6                862    12.9   
   Nurse practitioner                 537            55.1               3708   55.6   
  Weight (lbs)                                                                        
   \<150                              78             8.0                435    6.5    .186
   150-200                            293            30.1               2180   32.7   
   200-250                            193            19.8               1242   18.6   
   250+                               53             5.4                316    4.7    
  Not documented                      358            36.7               2496   37.4   
  Community-based outpatient clinic                                                   
   1                                  150            15.4               1841   27.6   \<.0001
   2                                  3              0.3                1191   17.9   
   3                                  821            84.2               286    4.3    
   4                                  0              0.0                1754   26.3   
   5                                  0              0.0                111    1.7    
   6                                  0              0.0                1099   16.5   
   7                                  1              0.1                310    4.6    
   8                                  0              0.0                77     1.2    
  *Medication use*                                                                    
  Testosterone                        27             2.8                158    2.4    .448
  Estrogen                            0              0.0                5      0.1    .392
  Corticosteroids                     16             1.6                223    3.3    .004
  Hormone deprivation therapy         11             1.1                45     0.7    .121
  Phenytoin                           2              0.2                31     0.5    .248
  *Comorbidities*                                                                     
  Alcoholism                          0              0.0                9      0.1    .251
  Smoking                             60             6.2                489    7.3    .183
  Rheumatoid arthritis                6              0.6                79     1.2    .113
  Diabetes                            43             4.4                167    2.5    .001
  Renal disease                       62             6.4                562    8.4    .028
  Stroke                              46             4.7                214    3.2    .015
  Fall risk                           20             2.1                137    2.1    .995
  Vitamin D deficiency                52             5.3                671    10.1   \<.0001
  Hyperthyroidism                     8              0.8                52     0.8    .893
  Prior fracture                      2              0.2                36     0.5    .165
  *Prior outcomes*                                                                    
  Dual-energy x-ray absorptiometry    5              0.5                59     0.9    .234
  Osteopenia diagnosis                23             2.4                77     1.2    .002
  Osteoporosis diagnosis              33             3.4                196    2.9    .446
  Vitamin D lab                       215            22.1               2671   40.1   \<.0001
  Osteoporosis medication             39             4.0                149    2.2    .001

Exposures and Outcomes {#section6-2150131916687888}
----------------------

The primary exposure was enrollment in the BHT, as evidenced by a chart note titled endocrinology bone health e-consult. The outcomes in our analysis were (*a*) completion of DXA scan, (*b*) completion of a 25-hydroxy-vitamin D measurement, (*c*) chart diagnosis of osteopenia, (*d*) chart diagnosis of osteoporosis, and (*e*) initiation of a fracture reducing medication. DXA, vitamin D measurement, and fracture reducing medication outcomes reflect actual events during the observation period. Chart diagnosis of osteopenia and osteoporosis are chart diagnoses that may reflect new or prior observations.

Analysis {#section7-2150131916687888}
--------

To measure the impact of BHT exposure on our outcomes, we constructed time-dependent, multivariable Cox proportional hazard models. In these models, patients were followed from the index date, February 1, 2013, until an event, or were censored on February 1, 2015. The BHT intervention began on February 1, 2013. All patients were unexposed and contributed person-time to the unexposed group unless and until they were exposed to BHT intervention, after which time they contributed person-time to the exposed group. The models adjusted for confounding on: age; sex; comorbidities, including alcohol abuse, smoking, diabetes mellitus, prior adulthood fracture, hyperparathyroidism, renal disease, and vitamin D deficiency; drug exposures, including anticonvulsants, aromatase inhibitors, androgen deprivation therapy, and testosterone; site of CBOC; and PCP discipline, including physician, physician assistant, or nurse practitioner. A separate regression model was constructed for each outcome.

Results {#section8-2150131916687888}
=======

Our cohort consisted of 7644 individuals, 975 of whom were exposed to the BHT and 6669 of whom were not. Descriptive statistics for these individuals are presented in [Table 1](#table1-2150131916687888){ref-type="table"}.

Unadjusted rates of each outcome are summarized in [Table 2](#table2-2150131916687888){ref-type="table"}. BHT participants had substantially higher rates of each outcome. This observation was most evident in the DXA and osteopenia outcomes with rate ratios of 76.72 (95% CI = 69.70-84.44) and 26.70 (95% CI = 23.22-30.71), respectively.

###### 

Surrogate Outcomes (Crude Rates) of Intermediate Outcome Measures of Primary Evaluation of Osteoporosis for Patients Enrolled in the Bone Health Team (BHT) Versus Patients Not Enrolled in the Bone Health Team (Non-BHT).

![](10.1177_2150131916687888-table2)

                                                                        BHT Patients, N = 975   Non-BHT patients, N = 6669   Rate Ratio                                                                               
  --------------------------------------------------------------------- ----------------------- ---------------------------- ------------ ------- ------- ------- ----------- ------- ------- ------- ------- ------- -------
  DXA                                                                   504                     249,465                      20.20        18.48   22.00   133     5,050,393   0.26    0.22    0.31    76.71   69.70   84.44
  Osteopenia^[a](#table-fn2-2150131916687888){ref-type="table-fn"}^     256                     374,741                      6.83         6.02    7.69    129     5,042,289   0.26    0.21    0.30    26.70   23.22   30.71
  Osteoporosis^[b](#table-fn3-2150131916687888){ref-type="table-fn"}^   147                     410,552                      3.58         3.03    4.18    239     4,989,201   0.48    0.42    0.54    7.47    6.28    8.90
  Medication^[c](#table-fn4-2150131916687888){ref-type="table-fn"}^     129                     430,588                      3.00         2.50    3.53    168     5,012,441   0.34    0.29    0.39    8.94    7.40    10.80
  25(OH)D ^[d](#table-fn5-2150131916687888){ref-type="table-fn"}^       369                     252,865                      14.59        13.14   16.12   3,883   3,370,423   11.52   11.16   11.89   1.27    1.14    1.41

Abbreviations: DXA, dual-energy x-ray absorptiometry; CI, confidence interval; LL, lower limit; UL, upper limit; 25(OH)D, 25-hydroxy-vitamin D.

Osteopenia---chart diagnosis of osteopenia.

Osteoporosis---chart diagnosis of osteoporosis.

Medication---medication order for bisphosphonate, denosumab, or teriparitide.

Vitamin D---serum 25-hydroxy-vitamin D lab completion.

To control for confounding we used Cox proportional hazard regressions. The hazard ratios (HRs) from univariate and multivariable Cox proportional hazards regressions are presented in [Table 3](#table3-2150131916687888){ref-type="table"}. Exposure to the BHT was associated with an increased likelihood of having each outcome when controlling for numerous known clinical risk factors for fracture. The effect sizes ranged from HR 1.619 (95% CI = 1.448-1.810) in the case of the vitamin D lab outcome to HR 139.9 (95% CI = 112.4-174.2) for completion of bone density screening (DXA).

###### 

Results From Univariate and Multivariate Cox Proportional Hazards Regression of Intermediate Outcome Measures of Primary Evaluation of Osteoporosis for Patients Enrolled in the Bone Health Team Versus Patients Not Enrolled in the Bone Health Team.

![](10.1177_2150131916687888-table3)

  Outcome                                                                Univariate Results   Multivariable Results                                             
  ---------------------------------------------------------------------- -------------------- ----------------------- ------- --------- ------- ------- ------- ---------
  DXA                                                                    111.4                90.9                    136.4   \<.0001   139.9   112.4   174.2   \<.0001
  Vitamin D^[a](#table-fn7-2150131916687888){ref-type="table-fn"}^       1.403                1.258                   1.564   \<.0001   1.619   1.448   1.810   \<.0001
  Medication^[b](#table-fn8-2150131916687888){ref-type="table-fn"}^      13.78                10.76                   17.64   \<.0001   17.03   12.78   22.70   \<.0001
  Osteopenia^[c](#table-fn9-2150131916687888){ref-type="table-fn"}^      36.34                29.01                   45.52   \<.0001   37.00   29.00   47.21   \<.0001
  Osteoporosis^[d](#table-fn10-2150131916687888){ref-type="table-fn"}^   11.22                9.01                    13.98   \<.0001   16.38   12.77   21.01   \<.0001

Abbreviations: DXA, dual-energy x-ray absorptiometry; HR, hazard ratio.

Vitamin D---serum 25-hydroxy-vitamin D lab completion.

Medication---medication order for bisphosphonate, denosumab, or teriparitide.

Osteopenia---chart diagnosis of osteopenia.

Osteoporosis---chart diagnosis of osteoporosis.

Discussion {#section9-2150131916687888}
==========

In this historical cohort study involving patients meeting age-based criteria for osteoporosis screening, we demonstrated that a dedicated team significantly improved rates of osteoporosis screening, diagnosis, and treatment. To our knowledge, no similar team based model for primary evaluation of osteoporosis has been described.

Our table of baseline characteristics showed that BHT patients were younger, more likely to live in rural areas, and more likely to have a physician as their PCP. BHT providers repeatedly followed up with patients, and coordinated bone density testing in conjunction with other appointments, which may have contributed to the BHT being more successful at addressing the travel needs of rural patients for completing DXA.

BHT offered universal bone density screening for men as young as 70 years and women as young as 65 years, as advocated by the National Osteoporosis Foundation.^[@bibr23-2150131916687888]^ Without a concerted effort to perform evidenced-based population level screening, patient demand is the typical impetus for accessing health care services. Until first fragility fracture, osteoporosis is a silent disease. Frailty, falls, independence, and previous fragility fracture, which increase patient demand for bone density screening, are more prevalent concerns for older patients. This lack of urgency for primary prevention likely contributes to the age disparity between BHT and non-BHT patients as well as the low rates of osteoporosis screening in standard care.

Our analysis has the strengths of being conducted in a comprehensive health care system with an integrated electronic medical record that allowed us to follow our patients longitudinally. Limitations of our study include that it is primarily conducted among elderly men, which may limit generalizability to women, although we reasonably theorize that a BHT could also benefit health systems with a higher proportion of females. Another limitation is that our analysis did not have the ability to compare fracture rates between BHT and standard primary care because of the long follow-up period and large sample size needed to identify these rare events.

Consideration should be given to future studies exploring access to DXA for rural patients; gaps in the understanding of importance of osteoporosis screening among patients, particularly men; fracture risk reduction; and the economic viability of the BHT model.

Conclusions {#section10-2150131916687888}
===========

Data from our historical cohort of primary care patients enrolled in the BHT showed significantly higher rates of osteoporosis screening with DXA and therapeutic intervention than current standard primary care practice, suggesting this phone-based, dedicated approach to osteoporosis screening and management may offer a viable method for the primary prevention of osteoporotic fractures.
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